Matthew Draelos, MD
Endocrinology, Diabetes & Metabolism · Edmond, OKNPI 1437221694
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Corcept Therapeutics at 28.2% of the total. Reporting peaked in 2019 at $40,365 and has fallen 67.3% since, to $13,206 in 2025. Among endocrinology, diabetes & metabolism clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,346 payments — averaging $81.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$31K
- AstraZeneca$24K
- Xeris Pharmaceuticals, Inc.$15K
- Merck$8K
- Bayer$6K
- Mannkind Corporation$5K
- plus $20K from 54 others
Across 48 payments — averaging $5891.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$283K
What the payments were for
- Consulting fees$20,15018%
- Speaking & faculty fees$55,99051%
- Travel & lodging$5,8995%
- Food & beverage$27,39925%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,669 in reported general payments places this provider in the 95th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 22 | $1,005,219 |
| OzempicSemaglutide | 467 | $628,368 |
| JardianceEmpagliflozin | 260 | $277,742 |
| FarxigaDapagliflozin Propanediol | 212 | $221,434 |
| MounjaroTirzepatide | 113 | $171,480 |
| Tresiba Flextouch U-200Insulin Degludec | 115 | $108,899 |
| TrulicityDulaglutide | 62 | $84,866 |
| RybelsusSemaglutide | 48 | $80,649 |
| KerendiaFinerenone | 65 | $69,613 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 65 | $64,856 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $55,287 |
| AfrezzaInsulin Regular, Human | 24 | $54,102 |
| Humalog Kwikpen U-200Insulin Lispro | 47 | $53,002 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 65 | $50,639 |
| VascepaIcosapent Ethyl | 71 | $40,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $30,907 | $1,005,21922 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $2,708 | $747,180561 claims |
| Boehringer IngelheimJardiance | $95 | $277,742260 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $274 | $263,650202 claims |
| AstraZenecaFarxiga | $23,555 | $221,434212 claims |
| BayerKerendia | $6,408 | $69,61365 claims |
| Mannkind CorporationAfrezza | $5,470 | $54,10224 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $821 | $29,14419 claims |
| MerckJanuvia | $8,180 | $26,26230 claims |
| AbbVieSynthroid | $2,099 | $13,354207 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $6,717677 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Edmond
- Cassie SmithEdmond$629K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Christian MangrumOklahoma City$54K
- Vaqar AhmadMidwest City$27K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Robert ScofieldOklahoma City$15K
- Lubna MirzaNorman$12K
- Donny WynnOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.